Jim Hughes A National Cancer Institute team led by Paul Meltzer recently published a paper in Science and Translational Medicine entitled, “Recurrent epimutation of SDHC in gastrointestinal stromal tumors.” The findings have some potential implications [...]
updated 1/20/21 Dr. mOe is an author, survivor, and dynamic mOe-tivational speaker. Diagnosed with GIST in 2012, Dr. mOe believes that God does not waste wounds. She is a freelance journalist, coach, mentor, [...]
With the onset of the patent expiration on Gleevec of the patent expiration on Gleevec for CML expiring in July and for GIST in June 2022 in the United States, it becomes more important than ever [...]
During the Life Raft Group Life Fest 2014, a panel of young GIST patients and family members gathered around a table to discuss ideas for advocating for SDH-deficient and wild type GIST. The group [...]
The GIST Group Switzerland recently awarded its Science Prize to Dr. Anette Duensing, Assistant Professor of Pathology at the University of Pittsburgh Cancer Institute, and a member of the LRG’s Research Team. GIST Group [...]
Wishes do come true. As part of our GIST 31 Wishes campaign, Assistant Program Director Mildred Menos’ wish was for every state in the US to be represented with one or more LRG leaders so [...]
The sixth annual Partnering for Cures meeting sponsored by FasterCures was held November 16-18 in New York City. Over 1,000 attendees from biopharma, governmental agencies, academia, philanthropy and patient advocacy organizations came together to [...]
Dr. Jason Sicklick On Saturday, January 24, the Moores Cancer Center in sunny San Diego played host to the first of our 2015 GIST Days of Learning. Nearly fifty GIST patients, caregivers, family [...]
Reprinted and revised from the February, 2011 LRG Newsletter. With Valentine’s Day looming, thoughts turn to relationships. There are often unrealistic expectations of the day: a dozen red roses, a satin heart filled with [...]
The National Health Service (NHS) in the United Kingdom has announced plans to halt funding through the Cancer Drug Fund for regorafenib (Stivarga), thereby preventing GIST patients from having access to this life-saving medication.We at [...]
